ClinicalTrials.gg
Not yet recruitingNCT07697690TEA-APODUpdated Jul 21, 2026

Thoracic Epidural Analgesia for Acute Pancreatitis With Early Organ Dysfunction

An interventional study of Thoracic Epidural Analgesia With Ropivacaine and conventional analgesia in Organ Dysfunction, Organ Support and Acute Pancreatitis (AP), sponsored by First People's Hospital of Chenzhou. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by First People's Hospital of Chenzhou · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Acute pancreatitis may cause early respiratory, cardiovascular, or renal dysfunction and may require intensive care and organ support. Thoracic epidural analgesia may improve pain control, reduce systemic opioid exposure, and facilitate gastrointestinal recovery; however, its effect on overall organ support burden remains uncertain.

This is a single-center, prospective, randomized, open-label, parallel-group clinical trial. A total of 150 adults with acute pancreatitis within 72 hours of symptom onset and early respiratory, cardiovascular, or renal dysfunction will be randomized in a 1:1 ratio to receive either ropivacaine-only thoracic epidural analgesia plus standard care or standardized conventional analgesia plus standard care.

The primary outcome is alive and organ support-free days through day 14 after randomization. Secondary and exploratory outcomes include alive and organ support-free days through day 28, organ dysfunction-free days, ventilator-free days, renal replacement therapy-free days, vasoactive drug-free days, 28-day mortality, pain scores, systemic opioid exposure, gastrointestinal and nutritional outcomes, intra-abdominal pressure, inflammatory markers, complications, length of stay, hospital costs, and adverse events related to thoracic epidural analgesia.

02

Conditions studied

  • Organ Dysfunction
  • Organ Support
  • Acute Pancreatitis (AP)

Browse trials for

Keywords

  • Thoracic epidural block
  • Ropivacaine
  • Organ support-free days
  • Opioid consumption
  • acute pancreatitis
03

In context

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

This study's planned enrollment of 150 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.

Browse Pancreatitis studies →

Lead sponsor

First People's Hospital of Chenzhou is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  1. Age 18 to 75 years, inclusive.
  2. Diagnosis of acute pancreatitis based on at least two of the following three criteria: typical acute upper abdominal pain; serum amylase and/or lipase at least three times the ; or imaging findings consistent with acute pancreatitis.
  3. Time from symptom onset to randomization of 72 hours or less.
  4. Early respiratory, cardiovascular, or renal organ dysfunction, defined as a SOFA-2 subscore of 2 or greater in at least one of these three organ systems, requiring ICU admission for continuous monitoring and treatment. The SOFA-2 score will be calculated using the worst available values during the 24 hours before randomization; for participants admitted to the ICU for less than 24 hours, values available since ICU admission will be used. The organ dysfunction must be newly developed or clearly worsened from the participant's previous stable baseline.
  5. Written provided by the participant or legally authorized representative.

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Chronic pancreatitis or acute pancreatitis associated with a pancreatic tumor.
  3. Prior retroperitoneal drainage, endoscopic drainage, surgical necrosectomy, or other invasive intervention before randomization that may substantially alter the natural course of the disease.
  4. Invasive mechanical ventilation before randomization.
  5. Any to thoracic epidural analgesia, including allergy to local anesthetics; infection at the puncture site; epidural abscess or central nervous system infection; severe spinal deformity or prior spinal surgery that prevents catheterization; intracranial hypertension or severe central nervous system disease; uncorrected coagulation disorder; or anticoagulant or antiplatelet therapy that does not meet neuraxial safety requirements.
  6. Uncorrected shock or persistent hemodynamic instability despite adequate fluid resuscitation and vasoactive drug support.
  7. End-stage renal disease requiring maintenance dialysis before randomization.
  8. Participation in another interventional clinical study within the previous 3 months.
  9. Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Thoracic Epidural Analgesia Group

    Participants will receive standard treatment for acute pancreatitis plus thoracic epidural analgesia using ropivacaine alone. After initial fluid resuscitation, blood pressure stabilization, and safety assessment, thoracic epidural analgesia will be initiated as soon as possible after randomization, preferably within 6 hours, no later than 24 hours after randomization, and before 72 hours from symptom onset. Epidural catheterization will be performed at T8-T11, preferably T9-T10 or T10-T11, by an investigator qualified to perform neuraxial procedures and trained in the study protocol. After a negative test dose of 1% lidocaine 3 mL, a loading dose of 0.2% ropivacaine 5-10 mL will be administered, followed by continuous infusion of 0.2% ropivacaine at 6-8 mL/hour. The target sensory block is T6-T12 and should cover the main upper abdominal pain area. Thoracic epidural analgesia will generally continue for 5 days or until ICU discharge if earlier. It may be extended to a maximum of 7

    Procedure: Thoracic Epidural Analgesia With Ropivacaine

  • Active comparator
    Conventional Analgesia Group

    Participants in this group will receive conventional analgesia and standard treatment for severe acute pancreatitis. Conventional analgesia may include non-steroidal anti-inflammatory drugs, acetaminophen, tramadol, fentanyl, sufentanil, oxycodone, hydromorphone, morphine, dexmedetomidine, or other analgesic and sedative medications according to clinical judgment. Analgesic drugs, doses, routes, duration of administration, rescue analgesia, sedative use, and opioid consumption will be recorded.

    Other: conventional analgesia

Interventions

  • ProcedureThoracic Epidural Analgesia With Ropivacaine

    Thoracic epidural block will be performed by an investigator qualified to perform neuraxial procedures and trained in the study protocol. Before catheterization, the clinical team will assess hemodynamic status, coagulation function, antithrombotic medication use, infection risk, respiratory status, and baseline neurological status. The puncture level will be selected according to the participant's condition and operator assessment, generally within the T7-T11 range to cover upper abdominal pain. After thoracic epidural catheter placement, a test dose of 1%-1.5% lidocaine 3 mL will be administered to exclude intrathecal or intravascular catheter placement. If the test dose is negative, a loading dose of ropivacaine may be administered, followed by continuous thoracic epidural infusion of ropivacaine alone. No epidural opioid, including sufentanil, fentanyl, or morphine, will be added to the epidural infusion in this study.

    Also known as: TEA, Thoracic epidural analgesia, Thoracic epidural blockade, Thoracic epidural catheterization

  • Otherconventional analgesia

    Conventional analgesia will be administered according to institutional practice and the participant's clinical condition. The analgesic target is an NRS score of 3 or less in conscious and communicative participants, or a CPOT score of 2 or less in non-communicative critically ill participants. Analgesic drugs, doses, routes, duration of administration, rescue analgesia, sedative use, and opioid consumption will be recorded.

    Also known as: Standard analgesia, Conventional pain management, Systemic analgesia

06

What researchers measure

Primary outcomes

  1. Alive and Organ Support-Free Days Through Day 14 (AOSFD-14)

    Alive organ support-free days to day 14 is defined as the number of days from randomization to day 14 during which the participant is alive and free of ICU-level organ support. ICU-level organ support includes invasive mechanical ventilation, noninvasive ventilation, continuous infusion of vasoactive or inotropic drugs, and renal replacement therapy. A day will be counted as organ support-free only if the participant is alive and does not receive any of these organ support treatments on that day. Participants who die within 14 days after randomization will be assigned 0 alive organ support-free days.

    Time frame: From randomization through day 14

Secondary outcomes

  1. Organ Failure-Free Days to Day 14

    Number of days from randomization to day 14 during which the participant is alive and free of respiratory, cardiovascular, and renal organ failure. Organ failure is defined as a SOFA subscore of 2 or higher in any of the following systems: respiratory, cardiovascular, or renal. Participants who die within 14 days will be assigned 0 organ failure-free days.

    Time frame: From randomization to day 14

  2. Alive Organ Support-Free Days to Day 28

    Number of days from randomization to day 28 during which the participant is alive and free of ICU-level organ support, including invasive mechanical ventilation, noninvasive ventilation, vasoactive or inotropic drug infusion, and renal replacement therapy. Participants who die within 28 days will be assigned 0 days.

    Time frame: From randomization to day 28

  3. Ventilator-Free Days to Day 28

    Number of days from randomization to day 28 during which the participant is alive and free of invasive mechanical ventilation. Participants who die within 28 days will be assigned 0 ventilator-free days.

    Time frame: From randomization to day 28

  4. Renal Replacement Therapy-Free Days to Day 28

    Number of days from randomization to day 28 during which the participant is alive and free of renal replacement therapy. Renal replacement therapy includes continuous renal replacement therapy and intermittent hemodialysis for acute kidney injury. Participants who die within 28 days will be assigned 0 days.

    Time frame: From randomization to day 28

  5. Vasoactive Drug-Free Days to Day 28

    Number of days from randomization to day 28 during which the participant is alive and free of vasoactive or inotropic drug infusion. Vasoactive or inotropic drugs include norepinephrine, epinephrine, dopamine, vasopressin, dobutamine, or other agents used for shock or circulatory support. Participants who die within 28 days will be assigned 0 days.

    Time frame: From randomization to day 28

  6. Pain Score

    Pain intensity will be assessed using the Numeric Rating Scale (NRS) in conscious and communicative participants, or the Critical-Care Pain Observation Tool (CPOT) in non-communicative critically ill participants. The NRS is an 11-point scale ranging from 0 (no pain) to 10 (worst possible pain). The CPOT ranges from 0 (no pain) to 8 (worst possible pain). For both scales, higher scores indicate worse pain control (worse outcome).

    Time frame: Baseline, 3-6 hours after intervention initiation, and days 1, 3, 5, and 7

  7. Analgesic Target Achievement Rate

    Total systemic opioid consumption during the first 7 days after randomization, converted to intravenous morphine equivalent dose when applicable.

    Time frame: From randomization to day 7

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data underlying the published results may be made available upon reasonable request after publication of the main study results. Data sharing will require approval by the principal investigator and the institution, and by the ethics committee when applicable. Data will be shared only for scientifically valid analyses and after signing an appropriate data use agreement.

Supporting information: Study protocol

Time frame: Beginning 6 months after publication of the main study results and available for 3 years.

Access criteria: Qualified researchers may submit a written request including research purpose, analysis plan, requested data elements, and data protection measures. Requests will be reviewed by the principal investigator and the institution.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697690
Lead sponsor
First People's Hospital of Chenzhou
Responsible party
Xingui Dai (Principal Investigator, First People's Hospital of Chenzhou) — Principal investigator
First posted
Jul 13, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Jul 21, 2026

Study contacts

Feng Yang, MM
Contact
202020321@sr.gxmu.edu.cn
+8615886524007
Xingui Dai, PHD
study chair · Chen Zhou NO.1 People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion